Open Orphan - Malaria Human Challenge Model Launched
ORPH Thu, 20 Jan 2022, 01:40pm GMT
hVIVO, a subsidiary of Open Orphan has inoculated the first cohort of volunteers with a GMP-manufactured malaria challenge agent as part of its first controlled human malaria infection challenge study.
Cathal Friel
Executive Chairman
Yamin 'Mo' Khan, Chief Executive Officer
Fri, 5 Aug 2022, 7:05am BST
Jeremy Skillington, CEO, Poolbeg Pharma
Mon, 18 Jul 2022, 7:00am BST
Dr. Andrew Catchpole, Chief Scientist
Tue, 14 Jun 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Tue, 7 Jun 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Fri, 6 May 2022, 7:05am BST
Yamin 'Mo' Khan, Chief Executive Officer
Mon, 28 Mar 2022, 9:00am BST
Robin Rogiers, Director Clinical Delivery & Innovation, hVIVO
Tue, 8 Mar 2022, 9:00am GMT
Cathal Friel, Executive Chairman
Thu, 24 Feb 2022, 7:00am GMT
Adrian Wildfire, Director of Scientific & Business Strategy, hVIVO
Mon, 14 Feb 2022, 10:30am GMT
Dr. Andrew Catchpole, Chief Scientist
Wed, 2 Feb 2022, 10:00am GMT
Cathal Friel, Executive Chairman
Wed, 2 Feb 2022, 10:00am GMT
Adrian Wildfire, Director of Scientific & Business Strategy, hVIVO
Thu, 20 Jan 2022, 4:30pm GMT
Cathal Friel, Executive Chairman
Thu, 20 Jan 2022, 1:40pm GMT
Cathal Friel, Executive Chairman
Fri, 10 Dec 2021, 9:06am GMT
Cathal Friel, Executive Chairman
Mon, 20 Sep 2021, 8:00am BST
Cathal Friel, Executive Chairman
Tue, 24 Aug 2021, 7:15am BST
Cathal Friel, Executive Chairman
Wed, 14 Jul 2021, 12:00pm BST
Management Team, Open Orphan
Mon, 14 Dec 2020, 7:00am GMT
